A supramolecular fluorescent probe targeting mitochondrial iron for assisting early Parkinson's disease diagnosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41886835.
- Also identified by DOI 10.1016/j.biomaterials.2026.124152.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early detection of Parkinson's disease (PD) before irreversible dopaminergic neuron loss remains a critical unmet need. Herein a novel supramolecular probe, DTPP@Q[7], was constructed via a host-guest assembly in which the fluorescent molecule DTPP is combined with the macrocycle cucurbit[7]uril (Q[7]) for real-time monitoring mitochondrial iron overload, an early pathological driver of PD. Encapsulation of DTPP fluorophore by Q[7] exposes the TPP targeting group, enabling precise mitochondrial localization (Pearson coefficient 0.95 with Mito-Tracker) while imparting higher photostability. The probe exhibits high selectivity and sensitivity for Fe<sup>3+</sup>, with a detection limit of 0.36 μM. Fluorescence quenching induced by mitochondrial Fe<sup>3+</sup> correlates with ferroptosis markers (ROS, GPX4, LPO, and MDA) in PD cells and tracks mitochondrial dysfunction, pathological α-synuclein aggregation, and altered dopamine synthesis, demonstrating dynamic reporting of neurodegenerative progression. In an MPTP mouse model, intranasal DTPP@Q[7] enables noninvasive monitoring of cerebral iron imbalance: probe fluorescence decreases dose-dependently and correlates with substantia nigra iron accumulation (R<sup>2</sup> > 0.99). In the high-dose MPTP group fluorescence fell by 76%, α-synuclein is upregulated ∼2.5-fold, and tyrosine hydroxylase expression drops nearly 40%. By capturing molecular pathology prior to neuronal morphological damage, DTPP@Q[7] offers a promising molecular strategy for early PD diagnosis.